**Actinomyces israelii** in the female genital tract: a review

D T P Evans

**Introduction**

In 1986 70 million women worldwide used the intra-uterine contraceptive device (IUCD) (see Part 2). Between 1·6 and 11·6% of IUCD users (see part 1) have infection with *Actinomyces israelii* (AI). Actinomyces is encountered from time to time in every sexually transmissible diseases clinic with periodic Papanicolaou (Pap) reports in IUCD users confirming the presence of AI. The issues of whether to treat with antibiotics or whether to remove the device or refer to the family planning clinic thus arise and confront the venereologist.

This review on AI is derived from journal articles spanning 64 years up to the present day (1992). The main body of the review is divided into four sections. Part 1 is concerned with actinomycoses in the female genital tract, focusing on detection methods, prevalence and demographic and geographic variables. The next section is involved with the effect of IUCD insertion. Part 3 is concerned with pelvic infection due to actinomycoses with emphasis on clinical presentation, diagnostic criteria and risk factors. Pelvic infection in this setting, it should be emphasised, is rare. The fourth part examines the management of the infected IUCD and of pelvic infection. Laparoscopy in diagnosis, the risk of pelvic actinomycoses, prevention and modern management of the latter, feature amongst some of the final issues.

**Part 1**

**Detection methods, prevalence and demographic, behavioural and geographic variables**

The first report of the association of actinomycoses-like organisms in the genital canals of women, employing the endocervical contraceptive device was by Barth in 1928.1 Actinomyces species are normal inhabitants of the oropharynx and possibly the bowel.2 Bhagavan3 in 1978 identified actinomycoses exclusively in patients wearing an intra-uterine or vaginal foreign body (intra-uterine devices and pessaries). Actinomycoses are anaerobic or microaerophilic. Dilution of samples which usually contain other anaerobes, the use of media containing 2·5 mg/l metronidazole, or special selective media are useful in achieving successful isolation. Cultures are often unsuccessful because the technique is poor, and this has persuaded many American workers to rely solely on microscopy of stained smears of material, sometimes confirming their impression by using direct immunofluorescent techniques. With the very wide range of coryneforms and lactobacilli present in the vaginal flora, the specificity of such techniques is critically important if they are used as the sole means of diagnosis. It is probable that such differences underly a controversy as to whether actinomycoses are normal members of the vaginal flora.4

Further work is needed to investigate the identity of the microcolonies, seen on Pap smears, that are not *Actinomyces israelii* and to confirm or refute whether actinomycoses such as *Actinomyces propionica* can be grown from the vaginas of patients without an IUCD in situ. It seems proper to regard these actinomycoses as part of the normal flora of patients with an IUCD in situ.4 Actinomycoses has been found, however, in Dybdahl’s 1991 series5 in a tiny percentage (2 of 17,734 cervical smears) of those without an intra-uterine device in situ (the latter represents 88% of the total); thus 12% of the women had an IUCD. However, in 1983 Persson et al6 stated that *Actinomyces israelii* was part of the indigenous genital flora. Dybdahl regarded actinomycoses in combination of the female genital tract as a rare event in women who are not users of IUCDs.

**Demographic and Geographic Variables and Prevalence**

Early reports of pelvic actinomycoses can be found in the literature in 1979 in Canada.7 The vast majority of reports of actinomycoses internationally over the years have been in intra-uterine contraceptive device (IUCD or IUD) users. The earliest (1982) and biggest study of women screened for AI by cervical Papanicolaou smears comes from the USA.8 The study was of 69,925 smears and the organism was not identified in non-IUCD users. The prevalence of AI among IUCD wearers ranged from 16% (general population) to 5% (clinic population).

In India the prevalence rate for actinomycoses in 1986 for 815 IUCD users was 6-99%.9 In India a year earlier Nayar et al found a 2-8% prevalence of actinomycoses in 350 cases using an IUCD. This was with pap smears confirmed by immunofluorescence.10 This pattern was maintained in Sweden6 and in Kuwait when AI was recovered only from IUCD users.11 In 1989 in Australia12 in IUCD users 11·6% of 973 cases had infection with AI, the majority of whom were asymptomatic.20

Lastly in Denmark in 1991 it was found that 8·6% of IUCD users had actinomycoses. Thus, there are reports of actinomycoses in association with IUCDs from North America,
Actinomyces in the female genital tract: a review

Scandinavia, Middle East, Australia and Asia. There is every reason to suspect that its ubiquitous in association with IUCDs and probably very rarely present worldwide in those without IUCDs.

Ethnic and behavioural differences in susceptibility to actinomycetes are issues that have not been addressed in the literature. For example, there have been no studies of differences between blacks and whites in America.

Detection methods Three species of actinomyces, A israelii, A naeslundii, and A odontolyticus, and a close relative Arachnia propionica are relevant to discussion of actinomycetes in the human genital tract. These bacilli are characteristically gram-positive and branching but can apparently occur as single bacilli looking not unlike coryneforms.4

Pine et al in 198113 set out to determine whether actinomycoses or arachniases species were common in the vaginas of apparently healthy women. They used a staining procedure in which peroxidase-conjugated rhodamine conjugate of normal rabbit globulin are used to reduce non-specific staining by fluorescein - conjugated antibody and the application of this procedure to demonstrate A israelii, A naeslundii and Arachnia propionica in cervicovaginal smears taken from apparently healthy women who had worn or who had not worn an IUCD. Earlier workers, including Gupta14 failed to find a smear positive for Actinomyces naeslundii (AN).

In later studies Gupta and collaborators identified AI in cervicovaginal smears by using fluorescein isothiocyanate (FITC) conjugates of species-specific globulins. Ultimately, actinomycete-like organisms were observed in stained smears from 520 women: in 250 out of 266 of these patients, AI was observed by staining with the FITC conjugate.13

Further diagnostic studies were performed using precipitin test antibodies against AI.6 15 In 1984, Persson and Holmberg used the latter system, comprising a combination of counter immuno-electrophoretic and crossed immuno-electrophoretic gel techniques. The specificity of the test system for the detection of cases of genital actinomycosis was 98% and the sensitivity was 83%. The accuracy was 100% for negative prediction and 45% for positive prediction. Thus the test was shown to be valuable for a non-invasive diagnosis of genital actinomycoses.

The same authors’ second study in 19856 was to detect a local antibody response to AI in uterine secretions of 100 women. There was an analysis by counterimmunoelectrophoresis for the occurrence of precipitation reactions against AI antigens. Precipitation reactions were found in secretions from seven women and they correlated with the long term use of plastic intrauterine devices. The precipitating components were not immunoglobulins, and their importance for AI colonisation and in disease development needs to be further investigated.

Leslie and Garland, from Melbourne, in 1991,16 compared direct immunofluorescence (IF) with traditional culture for the detection of AI. In a smaller sample than that of Cleghorn and Wilkinson, they examined endocervical and IUCD smears from 124 IUCD users of 11 specimens that gave positive results by immunofluorescence, only one was positive by culture. Thus they agree with Valcenti’s findings 9 years previously.8 This study16 however, crucially involved patients whose IUCDs had been in situ for less than 2 years, a significant difference from the other study. Thus, they would tend to favour immunofluorescence as the appropriate method. These workers criticised culture techniques as being insensitive, because of the oxygen-sensitive, fastidious and slow-growing nature of the organisms and difficulty in selecting them from other faster-growing anaerobes.

Examination of Pap-stained smears for AI is more sensitive than culture, but still lacks overall sensitivity and specificity. By morphology alone, AI, other genital actinomycoses, arachnia and nocardia are all indistinguishable: so this technique has its faults.

Overall direct immunofluorescence using fluorescein isothiocyanate labelled antisera against AI, is best and most sensitive and specific, although in some long term IUCD users (more than 36 months), culture and IF may be equally good for diagnosis.

A recent study by Dybdhal8 utilised old fashioned morphology as the means of identification of actinomycoses as used by Duguid,17 and Nayyar,10 in 1985. Such traditional methods still have their advocates. Actinomycoses was defined as the presence of dark, dense aggregates of uniformly sized filaments revealing distinct, acute-angle branching and radiation from a central core.5

Part 2

Effect of IUCD insertion (with reference to type of device and duration of its usage)

IUCD use involved 70 million women worldwide in 1986. In India 5-8 million women were fitted with IUCDs in the years 1981-1986.9

Valcenti states8 that an IUCD has been shown to induce a mild inflammatory response in the endometrium, with focal necrosis. This may produce an environment of anaerobiosis that encourages growth of A israelii and other anaerobic organisms. In his series of 112 cases in those patients whose IUCDs were removed and not replaced, subsequent Pap smears failed to reveal actinomycoses organisms. It could be concluded that in the vast majority of cases, the organism causes a superficial infestation of the endometrium, which is associated with the menstrual period. This is in contrast to true infection with associated tissue damage.

Pine13 observed the presence of AI, A naslundii, and Arachnia propionica in cervicovaginal smears from women, who did use and, who did not use an IUCD AI was commoner in women using an IUCD but, there was no evidence that the use of an IUCD
influenced the presence of either A propionica or A naeslundi (AN).

Bonroz in 1985 was the first to demonstrate AN as a causative agent of pelvic actinomycoses in the presence of an IUCD. In the 1982 study of Valicenti, the 212 IUCD users who had AI had an average of 6.1 years of IUCD usage. The types of IUCD were as follows:

<table>
<thead>
<tr>
<th>Type</th>
<th>Average duration (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lippe's Loop</td>
<td>36</td>
</tr>
<tr>
<td>Dalkon Shield</td>
<td>20</td>
</tr>
<tr>
<td>Saf-T-Coil</td>
<td>20</td>
</tr>
<tr>
<td>Unknown</td>
<td>15</td>
</tr>
<tr>
<td>Tatum-T</td>
<td>8</td>
</tr>
<tr>
<td>Cu-7</td>
<td>1</td>
</tr>
</tbody>
</table>

Nayar et al. discovered that the time of insertion of an IUCD (postpuerlal post-menstrual or after medical treatment of pregnancy) did not show any correlation with the presence of actinomycoses infection. Duguid et al. emphasised that a significantly greater colonisation of actinomycoses-like organisms are found in women with plastic devices, when compared with copper device users. Persson alludes to this predisposition for plastic. The antibacterial effect of copper is known, and reports have shown that following insertion, such devices release about 27 micrograms of copper daily and this amount decreases with time. It may merely be a reflection of the fact that copper IUCDs are changed more frequently than the plastic ones.

Data from India suggest that prolonged use (more than 2 years) of an inert or copper IUCD promotes the overgrowth of actinomycoses in the vagina and, in turn, this can be detected by routine cervical cytology. A fairly recent report (1989) showed that the incidence of AI in the female genital tract of IUCD users was more than doubled when the IUCD was worn for longer than 4 years. The type of IUCD worn did not appear to be an important risk factor. Local fashions appear to govern type and popularity of devices.

Cleghorn and Wilkinson showed that immunofluorescent staining of cervical smears identified 64% of cases of AI. Specific cultivating for AI or cytological screening of Pap smears, in addition, were required to increase the isolation rate to nearly 90%. The data in this paper support the view that IUCDs should be changed every 4 years. Only the Dalkon Shield and Saf-T-Coil, amongst all IUCDs were associated with a statistically significant detection rate of AI in this study. Other IUCD types were: Lippe S Loop; Grafenber Ring; Copper 7; Gyna-T (Copper T); Multiloop (Copper 250).

Cleghorn and Wilkinson showed that for diagnosis, culture for actinomycoses was more reliable when the IUCD had been in place for more than 36 months, suggesting that these were more advanced cases. Immunofluorescence of cervical smears for AI is most useful for short term IUCD users, when culture is less reliable. Cytology was the least sensitive technique, and no cases of actinomycoses were detected when the IUCD had been worn for less than 12 months.

**Part 3** Incidence of pelvic infection due to actinomycoses. Clinical presentation, diagnostic criteria and risk factors

There is a need for careful differentiation between the presence of AI of the female genital tract and pelvic actinomycotic disease. The latter is very rare.

Valicenti stated that sporadic case reports have implicated this organism as the aetiology agent in salpingo-oophoritis, tubo-ovarian abscess, and endometritis in women using IUCDs. Because the morphology of the actinomycete may be variable and dependent on growth conditions, A israelii often is confused with other Gram-positive, non-sporo-forming bacilli and non-related bacteria such as clostridia, corynebacteria, listeria, and leptotrichia. Actinomycetes are not cultured or isolated readily from cervical material using basic anaerobic media, which makes confirmation difficult. Direct immunofluorescence using fluorescein isothiocyanate-labelled antisera against A israelii is sensitive and specific and has become the method of choice for positive identification.

Bhagavan and Gupta stated that the symptoms and signs of actinomycoses in the genital tract of IUCD users, which could possibly be the harbinger of more serious pelvic actinomycosis. In this series there were: vaginal discharge in 17; pelvic pain in 4; pelvic and abdominal pain in 2; menorrhagia/intermenstrual bleeding in 3; fever in 2; pelvic mass in 2; history of pelvic inflammatory disease (PID) in 3.

Cleghorn and Wilkinson found that the detection of A israelii in the female genital tract was associated with an almost four-fold increase in the incidence of PID indicating that colonisation may progress to an infection in a small number of women in the endometrium and fallopian tubes under appropriate conditions of tissue damage. This is controversial see start of section 2. At present there is no way of predicting which IUCD patients who are colonised with AI will subsequently develop serious pelvic infection.

Leslie and Garland stated in 1991 that reports of actinomycoses species in cases of PID in IUCD users has varied from 17% to 25%. In association with this it must be borne in mind that the prevalence of actinomycoses carriage in IUCD users (as implied in part 1) varies from 1.6% to 11.6% in different series.

Spread of AI within and without the genital tract is uncommon, but when it occurs, the right uterine tube is usually affected, with or without parametrial disease. The uterus appears to be relatively resistant to infection and endometrial involvement is extremely rare.

O'Brien in 1975 reported a case of endometrial infection with AI associated with an IUCD, and presence of AI in inflamed...
Actinomyces israelii in the female genital tract: a review

omeental and pericolic tissues. The staining reactions of AI were present in tissue adherent to the IUCD, that is not Ziehl-Neelson acid-fast, yet positive for Grocott's modification of Gomori's methenamine silver nitrate stain. Also, radially arranged, gram positive, beaded, branching filaments, typical of AI were observed in the specimen.

Indeed pelvic actinomycases in 1976 was considered one of the rarer diseases confronting the gynaecologist, with only 300 cases reported then.²⁰ It is insidious in onset and clinically indistinguishable from other forms of PID. However, in 1976 anaerobic culture and histological analysis of the surgically treated pelvic abscess had a high failure rate for identification of the organism.²⁰ Lomax et al presented four cases of actinomyces involving the uterus and adnexal structures collected over a 20 year period (1954–1974) at the University of Virginia. In two patients IUCDs were associated with endometrial actinomycosis and adnexal abscesses.

The difficulty encountered in identifying AI indicates that the infection is often undetected (pelvic actinomycosis is usually confined to the tubes, ovaries, uterus and parametrium. Tubo-ovarian abscesses are part of the spectrum). Hence the value of Pap cervical smears for early detection and prophylactic treatment before AI has been well established (see below). Gallium 67 and indium scans are helpful in localising late disease, that is occult abscesses as suggested by Lomax et al.²⁰ Laparoscopy has its place (see Part 5) as does ultrasound of ovaries and pelvis. Magnetic resonance imaging and computed tomography of the abdomen and pelvis could be useful in diagnosis of focal abscesses. Lastly culdocentesis is an adjunct to diagnosis.

Treatment of pelvic actinomycases, as recommended by Lomax, is a combination of high doses of penicillin and chloramphenicol to treat the anaerobes. Oral penicillin should then continue for at least 2 months.

Cohen and Silberberg in 1976 reported a case of an extensive tubo-ovarian abscess caused by AI. They warn that when chronic PID does not respond to therapy, when the sedimentation rate remains high, and the patients general debility is progressing, an actinomycotic infection should be suspected. Their therapeutic advice was to extirpate the infected tissue in combination with penicillin.²² This could include salpingo-oophorectomy and hysterectomy.

In 1976 the reported locations of all known cases of pelvic actinomycosis were reviewed.²² Cases were recorded at the time of diagnosis. Whether medical treatment had been given or not was immaterial. These essentially were abscesses or ‘foci’ of infection. Thus there were, up to 1976, 66 cases of actinomycotic tubo-ovarian abscesses in the world literature. Eighteen were in the fimbria on the right, nine were in the fimbria on the left, 18 were in the ovary on the right, 21 were in the ovary on the left, seven were in the uterus, 12 were in the adnexus on the right, 12 were in the adnexus on the left, nine were in the parametrium on the right, nine were in the parametrium on the left.

There is a need for sophisticated anaerobic culture from female pelvic infection or abscesses; culture from female pelvic infection or abscesses; culture for actinomycoses requires prolonged incubation.²³

Part 4
Management of infected IUCD and of pelvic infection

Valicenti et al⁸ recommended conservative management for asymptomatic patients, with cytologically detected AI, to include removal of the IUCD, and repeated Pap smear after the next menstrual period. Subsequent investigation invariably fails to identify actinomyces-like organisms. The organism may cause a superficial endometritis, which is shed with the menstrual period: this appears to be a very satisfactory approach.

There is common agreement that in PID with actinomycoses infection, removal of the IUCD and antibiotics are mandatory. When actinomycoses are present without any evidence of PID, some operators would treat conservatively and not remove the IUCD.⁵ The vast majority would, however, in this circumstance, remove the IUCD and repeat the Pap smear after the next menstrual period.⁸ Should it be negative, some might replace it with a fresh IUCD.

The views of Cleghorn and Wilkinson¹² are pertinent here. They state that there is no way of predicting which IUCD patients, who are colonised with AI, will subsequently develop serious pelvic infection. Therefore, all IUCD users, with symptoms of possible PID, should be screened for AI so that antibiotic treatment and/or IUCD removal can be carried out, to prevent the colonisation progressing to pelvic infection.

Leslie and Garland¹⁶ in 1991 reminded us that management of IUCD users with actinomycoses is arbitrary and varies from centre to centre. They advocate 2 yearly immunofluorescence tests, of a cervical smear, and if asymptomatic actinomyces carriage is discovered, removal of the device. Earlier cervical smears would be done if the patient was symptomatic.

If the IUCD user presents with localised symptoms, then amoxicillin 500 mgs tds and metronidazole 400 mgs bd or tds doxycycline 100 mgs bd for 2-3 weeks are given and the device is removed. Pelvic actinomycoses is a potentiating life threatening disease but fortunately rare.

If a pelvic mass is present, aggressive and prolonged antibiotic therapy plus possible surgery is required (see part 3). Sexually Transmissible Disease Clinics becoming “Sexual Health Centres” with Family Planning expertise may, in the future, more often take part in the removal of IUCDs. Of course, there would be simultaneously monitoring of the contraceptive wishes of the
patient and this is the overriding consideration in this whole debate.

Part 5
How pelvic actinomycosis resembles and differs from other forms of PID

The incidence of PID, in general, is reported to be higher in IUCD users than in non-users, although the type of IUCD, patient selection, and the presence of sexually transmitted organisms are important factors in assessing the real risk.16

Vessey et al reported hospital admission rates in the United Kingdom with a diagnosis of acute PID to be 1.5-1 per 1000 women for IUCD users compared with 0.14/1000 for non-users. They found the Dalkon Shield (now withdrawn) to be associated with the highest risk and copper containing devices to be associated with the lowest risk.24

Recent observations appear to indicate a cause and effect relationship between use of IUCDs and pelvic actinomycosis. The relationship between presence of actinomyces-like organisms in the cervical smears of IUCD users, and the subsequent development of PID, is more difficult to establish, because the majority of such cases are asymptomatic at the time of smear collection and may remain so for a considerable length of time.6

It was formerly thought that the lactinomycotic route of entry in PID and mode of spread was via local lymphatic pathways from the gastrointestinal tract and haematogenous pathways during systemic infection.3 The reality is an ascending route of infection via the IUCD.3 This route of infection in actinomycotic PID is the same as for PID in general; namely upward spread through the cavities of the cervix, uterine body and tubes.24

Laparoscopy appears to be a useful method to diagnose AI in PID in general. Blihmmer from Sweden in 198726 laparoscoped 359 patients to verify the diagnosis of salpingitis. PID was found in 52% of the cases. Bacteriological cultures from the fimbrial lumen and/or pouch of douglas revealed AI in 3% compared with Chlamydia trachomatis in 12% and bacteroides in 5%.26

Symptoms and signs criteria for inclusion in this study were symptoms of less than 3 weeks duration of low abdominal pain, vaginal discharge and tenderness at gynaecological examination.26

The usefulness of laparoscopy is demonstrated by the fact that completely normal inner genitalia were found in more than one third of the cases. Irregular bleeding, an ESR above 15 mm in 1 hour and temperature above 38°C in this study constituted significant signs for the diagnosis of salpingitis in general. Whether this relationship and predictive valve holds for AI PID alone is not known.

Large series of laparoscopically verified cases of AI in PID need to be studied in detail to answer such questions as to how the symptom and sign profile of such patients, differs if at all from classical non AI cases of PID. Do AI cases of PID have the same complications profile as PID in general? The answers are not known. Long-term infertility, ectopic pregnancy and chronic pelvic pain are all in question.

The risk of pelvic actinomycosis: a summary
How may pelvic actinomycosis be prevented? Perhaps long-term penicillin or doxycycline could be tried in IUCD users. Long-term amoxycillin or flagyl are not practicable. The simple answer is to change the IUCD every 4 years. It should be suspected in any long-term IUCD user. How is it diagnosed? It is diagnosed by a Pap smear backed up by culture and immunofluorescence. Laparoscopy or CT are adjucats. Advanced cases may require laparotomy (see previous sections).

Modern management
Most authors agree that for a small or moderate size pelvic abscess (up to 8 cm maximum diameter), medical treatment is worth a trial.27 It would appear that penicillin or another beta lactam antibiotic, aminoglycoside and an agent such as metronidazole, highly active against anaerobes, should all be used together. Careful monitoring of the clinical state of the patient is needed, including if possible ultrasound assessment of the size of the abscess. If any worsening occurs, or if distinct improvement in her condition is not apparent within 48-72 hours of starting treatments, then surgical treatment is needed.27
All studies report a very poor fertility prognosis after antibiotic treatment for pelvic abscess complicating PID.

Recently an international team28 have reviewed the World Health Organisation's IUCD clinical trial data to explore the incidence and patterns of PID (in general as opposed to specifically AI induced) risk with use of an IUCD. After adjustment for confounding factors PID risk was more than six times increased relative to a placebo intervention than during later times. The findings indicated that PID among IUCD users is most strongly related to the insertion process and to background risk of STDs. The authors state that IUCDs should be left in place up to their maximum lifespan and they do not focus on the long-term potential actinomycosis risk. So, in conclusion, based on these data, and the findings in this review, PID risks are at the start and the end of the life of the IUCD.

Lastly here is the devil's advocate in this review:— Is there good evidence that actinomycosis is a primary pathogen, or does it occur as a complication of some common causes of PID, because of inadequate treatment for anaerobic secondary infection? The simple answer to this question is that it is not known; however, Leslie and Garland16 expand on this issue. They say that in most cases PID is polymicrobial, with various aerobes and anaerobes in addition to sexually transmitted organisms, the commonest of which is Chlamydia trachomatis.
Conclusions

The process of colonisation of an IUCD by 
AI is slowly progressive, since there is little change in rate of AI detection before a IUCD 
has been in situ for 48 months. The incidence 
is increased to a maximum of over 30% 
colonisation of IUCD by AI after 8 years. 

Immunofluorescence and culture are the 
best methods of detection of AI. 

There is a need to try and determine which 
IUCD wearers are colonised with A.I., and 
subsequently develop serious pelvic infection. 

Plastic IUCDs are more likely to be 
colonised by actinomyces like organisms than 
copper devices. 

AI in the female genital tract of IUCD 
users more than doubles (in incidence) when 
the IUCD is worn for longer than 4 years. 
For this reason it is prudent to change 
IUCDs every four years. Pelvic actinomyces 
is indistinguishable from other forms of PID. 
All IUCD users with symptoms of possible 
PID should be screened for AI so that 
appropriate treatment can be given. Laporoscopic 
bacteriological culture from the fimbrial 
lumen is the best method of confirmation of 
AI pelvic inflammatory disease. 

PID is mostly polymicrobial with a combina- 
tion of various aerobes and anaerobes. 

Plans for treatment of AI: In asympto- 
matics with actinomyces, remove IUCD and 
possibly replace later if certain conditions are 
satisfied. With asymptomatics it is necessary 
to review the contraceptive wishes of the 
patient, before putting another IUCD back in 
situ. With all PID cases, the IUCD must be 
removed, followed by antibiotic treatment. 

It is questionable whether the IUCD 
should be left in place in asymptomatics, and 
also whether to leave the IUCD in place with 
antibiotic “cover” in PID. 

For pelvic actinomycosis treatment it is 
prudent to use a surgical approach for tubo- 
ovarian abscesses greater than 8 cm diameter 
and to reserve medical treatment for the rest. 

It seems to be established that actinomyces 
can be grown from the vaginas of patients 
without an IUCD in situ. Thus, we have no 
need to adhere to the belief that AI is not a 
commensal in the vagina, but is introduced 
there via oral sex. 

I thank Lorraine Cleary for her considerable patience with 
typing the manuscript and drafts. 

1 Barth H. Uber Paramytritis Actinomyctozia und ihre 
Enstehung Arch Gynaekol 1928;134:310-21.
Actinomyces israelii in the female genital tract: a review.

D T Evans

*Genitourin Med* 1993 69: 54-59
doi: 10.1136/sti.69.1.54

Updated information and services can be found at:
[http://sti.bmj.com/content/69/1/54.citation](http://sti.bmj.com/content/69/1/54.citation)

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)